Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus

seekingalpha04-26

While Gilead Sciences' (NASDAQ:GILD) Q1 2024 financial results beat on both the top and bottom lines, it provided updated 2024 guidance ranges. One of those updates was to non-GAAP diluted EPS for the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2430526566?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1256967870/image_1256967870.jpg","is_english":true,"pubTime":"2024-04-26 06:55","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2430526566","market":"hk","top_or_hot":-1,"title":"Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus","media":"seekingalpha","content":"<div>\n<p>While Gilead Sciences' (NASDAQ:GILD) Q1 2024 financial results beat on both the top and bottom lines, it provided updated 2024 guidance ranges. One of those updates was to non-GAAP diluted EPS for the...</p>\n\n<a href=\"https://seekingalpha.com/news/4094663-gilead-strong-q1-but-updated-2024-eps-guidance-range-misses-consensus\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead has strong Q1, but updated 2024 EPS guidance range misses consensus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-26 06:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4094663-gilead-strong-q1-but-updated-2024-eps-guidance-range-misses-consensus><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While Gilead Sciences' (NASDAQ:GILD) Q1 2024 financial results beat on both the top and bottom lines, it provided updated 2024 guidance ranges. One of those updates was to non-GAAP diluted EPS for the...</p>\n\n<a href=\"https://seekingalpha.com/news/4094663-gilead-strong-q1-but-updated-2024-eps-guidance-range-misses-consensus\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4566","symbol_name":"资本集团","start_time":0,"source_url":"https://seekingalpha.com/news/4094663-gilead-strong-q1-but-updated-2024-eps-guidance-range-misses-consensus","article_id":"2430526566","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1256967870/image_1256967870.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2430526566","pubTimestamp":1714085725,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"While Gilead Sciences'  Q1 2024 financial results beat on both the top and bottom lines, it provided updated 2024 guidance ranges. One of those updates was to non-GAAP diluted EPS for the year. The biopharma now sees it coming in at $3.45-$3.85, from $6.85-$7.25 prior. Consensus is $3.93.  Gilead swung to a diluted EPS loss of $ in Q1 compared to EPS of $0.80 in the year-ago period. The company explained this was primarily because of an acquired in-process research and development charge of $3.9B, or $3.14 per share, related to its acquisition of CymaBay Therapeutics. Also, the company took a pre-tax IPR&D impairment of $2.4B, or $1.46 per share, related to assets acquired from Immunomedics in 2020.   More on Gilead Sciences  Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?Gilead Sciences: Some Signs Of An Impending Bottom Gilead Sciences Finally Starts Succeeding Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M Gilead Science","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4566":"资本集团","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4578":"CAR-T","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","GILD":"吉利德科学","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","BK4583":"猴痘概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4532":"文艺复兴科技持仓","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"吉利德Q1强劲，但更新的2024年每股收益指导范围未能达成共识","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"While Gilead Sciences' (NASDAQ:GILD) Q1 2024 financial results beat on both the top and bottom lines, it provided updated 2024 guidance ranges. One of those updates was to non-GAAP diluted EPS for the year. The biopharma now sees it coming in at $3.45-$3.85, from $6.85-$7.25 prior. Consensus is $3.93.  Gilead swung to a diluted EPS loss of $(3.34) in Q1 compared to EPS of $0.80 in the year-ago period. The company explained this was primarily because of an acquired in-process research and development charge of $3.9B, or $3.14 per share, related to its acquisition of CymaBay Therapeutics. Also, the company took a pre-tax IPR&D impairment of $2.4B, or $1.46 per share, related to assets acquired from Immunomedics in 2020.   More on Gilead Sciences  Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gilead Sciences: Some Signs Of An Impending Bottom Gilead Sciences Finally Starts Succeeding Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430526566"}